[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367934-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367934-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","synergistic-effects-of-the-curcumin-analog-ho-3867-and-olaparib-in-transforming-fallopian-tube-epithelial-cells","Synergistic effects of the curcumin analog HO-3867 and olaparib in transforming fallopian tube epithelial cells","","Ovarian cancer remains highly lethal due to frequent recurrence and treatment-related toxicities. While PARP inhibitors such as Olaparib benefit primarily BRCA-mutated tumors, broader patient populations lack effective targeted options. This study tests HO-3867, a curcumin analog known to restore mutant p53 function, alone and with Olaparib in fallopian tube-derived ovarian cancer models carrying mutant or null TP53. Binding of HO-3867 to the p53Y220C core domain is supported by molecular docking and CETSA. Functional assays using SRB, flow cytometry, and Western blotting show HO-3867 elevates phospho-p53 (Ser15) and p21, induces G1 arrest, and reduces viability. Co-treatment synergistically increases apoptosis, with caspase-3 activation, PARP1 cleavage, and enhanced γH2AX, indicating potentiation through amplified DNA damage. Results support HO-3867 as a p53-reactivating strategy to enhance Olaparib efficacy in TP53-mutant ovarian cancer.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/synergistic-effects-of-the-curcumin-analog-ho-3867-and-olaparib-in-transforming-fallopian-tube-epithelial-cells/367934/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/synergistic-effects-of-the-curcumin-analog-ho-3867-and-olaparib-in-transforming-fallopian-tube-epithelial-cells/367934.png","ImageObject",300,407,{"name":42,"@type":43},"Anna Hans","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address in ovarian cancer treatment?","Question",{"text":63,"@type":64},"The study targets the high recurrence and toxicity of current therapies, and the limited effectiveness of PARP inhibitors mainly in BRCA-mutated patients.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was HO-3867 shown to interact with mutant p53?",{"text":68,"@type":64},"Molecular docking and cellular thermal shift assays (CETSA) supported HO-3867 binding to the p53Y220C mutant core domain.",{"name":70,"@type":61,"acceptedAnswer":71},"What biological effects did HO-3867 and Olaparib show alone and in combination?",{"text":72,"@type":64},"HO-3867 increased phospho-p53 (Ser15) and p21, caused G1 arrest, and suppressed viability. Together with Olaparib, it synergistically enhanced apoptosis, including caspase-3 and PARP1 cleavage and increased γH2AX.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367934,1790481642,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},5909892332657,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Investigational New Drugs (2025) 43:857–873  \n[https://doi.org/10.1007/s10637-025-01571-2](https://doi.org/10.1007/s10637-025-01571-2)  \nSynergistic effects of the curcumin analog HO‑3867 and olaparibin transforming fallopian tube epithelial cells  \nCai‑Chieh Tseng1 · Min‑Hsi Ku1 · Wei‑Min Wu2 · Ava Mendez3 · Tessa Christner3 · Yun‑Chieh Wu1 · Wei‑Lun Huang1 · Yu‑Hsiang Chen1 · Ching‑Wen Huang1 · Johnathan Barefoot3 · Chi‑Wei Chen1,3  \nReceived: 16 May 2025 / Accepted: 22 July 2025 / Published online: 4 August 2025 © The Author(s) 2025  \nSummary  \nOvarian cancer remains one of the most lethal gynecologic malignancies, largely due to high recurrence rates and treatmentrelated toxicities. Although PARP inhibitors like Olaparib have shown efficacy in BRCA-mutated cancers, their benefit is limited in broader patient populations. TP53 mutations, highly prevalent in ovarian cancer, promote tumor progression and resistance, making p53 a key therapeutic target. This study evaluated the anticancer potential of HO-3867, a curcumin analog known to restore mutant p53 function, alone and in combination with Olaparib. We used fallopian tube-derived ovarian cancer models harboring mutant or null TP53 and analyzed TP53 expression and mutation profiles using TCGA datasets. Molecular docking simulations and cellular thermal shift assays (CETSA) confirmed HO-3867 binding to the p53Y220C mutant core domain. Cytotoxicity was assessed via SRB assays; flow cytometry and Western blotting were used to examine cell cycle progression, apoptosis, and DNA damage. HO-3867 treatment increased phospho-p53 (Ser15) and p21 expression, induced G1 phase arrest, and suppressed cell viability. Notably, co-treatment with Olaparib synergistically enhanced apoptosis, as indicated by increased caspase-3 and PARP1 cleavage and elevated γH2AX levels. These findings suggest that HO-3867 reactivates mutant p53 and potentiates Olaparib efficacy by promoting apoptosis and amplifying DNA damage, offering a promising therapeutic strategy for TP53-mutant ovarian cancer.  \nKeywords HO-3867 · Curcumin analog · PARP inhibitor · TP53 · Transforming fallopian tube epithelial cells · Ovarian cancer  \nIntroduction  \nOvarian cancer is one of the most prevalent and lethal gynecological malignancies, accounting for the highest mortality rate among reproductive system cancers in women [1, 2] . Despite advancements in surgery, radiotherapy, and chemotherapy, the prognosis remains poor due to high recurrence rates, metastasis, and the development of resistance to  \n* Chi-Wei Chen[chenc4@appstate.edu](chenc4@appstate.edu)  \n1 Department of Biochemical and Molecular Medical Sciences, College of Science and Engineering, National Dong Hwa University, Hualien 974301, Taiwan, R.O.C.  \n2 Department of Natural Resources and Environmental Studies, College of Environmental Studies, National Dong Hwa University, Hualien 974301, Taiwan, R.O.C.  \n3 Department of Biology, College of Arts and Sciences, Appalachian State University, Boone, NC 28608, USA  \nstandard therapies [3] . While PARP inhibitors have shown therapeutic promise, their efficacy is confined mainly to patients with BRCA mutations, leaving a substantial proportion of cases without effective targeted treatment options [4] . This underscores the urgent need for innovative therapeutic strategies that can address the broader ovarian cancer patient population. Given its aggressive nature, poor clinical outcomes, and limited treatment options, ovarian cancer represents a critical and unmet medical challenge that demands the development of more effective and inclusive therapeutic approaches.  \nThe TP53 gene, frequently mutated in ovarian cancer, especially in high-grade serous ovarian carcinoma (HGSOC), encodes a protein that regulates cell division and prevents uncontrolled cell growth [5] . The earliest detectable transformation of the fallopian tube fimbrial epithelium (FTE) is lesions involving TP53 mutations, characterized by an accumulatio","cbCaieCGL6LBfU5F","https://ap.wps.com/l/cbCaieCGL6LBfU5F","pdf",2325738,17,"English","# Summary\n# Introduction\n## Background: ovarian cancer and recurrence\n## PARP inhibitor limitations\n## TP53 mutations and fallopian tube origins\n## HO-3867 as a p53 restorer\n# Study approach and assessments","[{\"question\":\"What problem does the study address in ovarian cancer treatment?\",\"answer\":\"The study targets the high recurrence and toxicity of current therapies, and the limited effectiveness of PARP inhibitors mainly in BRCA-mutated patients.\"},{\"question\":\"How was HO-3867 shown to interact with mutant p53?\",\"answer\":\"Molecular docking and cellular thermal shift assays (CETSA) supported HO-3867 binding to the p53Y220C mutant core domain.\"},{\"question\":\"What biological effects did HO-3867 and Olaparib show alone and in combination?\",\"answer\":\"HO-3867 increased phospho-p53 (Ser15) and p21, caused G1 arrest, and suppressed viability. Together with Olaparib, it synergistically enhanced apoptosis, including caspase-3 and PARP1 cleavage and increased γH2AX.\"}]","Synergistic effects of the curcumin analog HO-3867 and olaparib in transforming fallopian tube epithelial cells | PDF",1790173391,43,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/921c50b758cfd08d86ff85f2fd1ca375.webp",983,1305,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6bd94b493ce3706f0f3070aad201be6a.webp",982,1304,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/164aaf43c0906deb126971fad77e1c4e.webp",981,1303,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa6a0e596ae30d7fc2de256a2afb5283.webp",980,1301]